57
Participants
Start Date
January 31, 2008
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2010
Lamotrigine regular tablet formulation
Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.
Lamotrigine novel formulation
"Participants will have the option of trying a novel formulation of lamotrigine tablets instead of the lamotrigine regular formulation tablets. The dosing will remain the same regardless of which type of lamotrigine tablet is used.~Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds."
Weill Medical College of Cornell University, White Plains
University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh
University of Pennsylvania, Philadelphia
University Hospitals Case Medical Center/ Case Western Reserve University, Cleveland
Baylor College of Medicine/Michael E. DeBakey VAMC, Houston
Collaborators (1)
GlaxoSmithKline
INDUSTRY
University Hospitals Cleveland Medical Center
OTHER